Zidovudine (AZT) for Treatment of Patients Infected With Human Immunodeficiency Virus Type 1: An Evaluation of Effectiveness in Clinical Practice
Colson E, Horwitz R, Bia F, Viscoli C. Zidovudine (AZT) for Treatment of Patients Infected With Human Immunodeficiency Virus Type 1: An Evaluation of Effectiveness in Clinical Practice. JAMA Internal Medicine 1991, 151: 709-713. DOI: 10.1001/archinte.1991.00400040061014.Peer-Reviewed Original ResearchZidovudine therapyDosage reductionAdverse outcomesHuman immunodeficiency virus type 1 (HIV-1) infectionClinical practiceHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Observational cohort studyHuman immunodeficiency virusTreatment of patientsType 1 infectionVirus type 1Zidovudine dosageCohort studyMost patientsImmunodeficiency virusBaseline cytopeniasTreatment outcomesPatterns of usePatientsTherapyType 1Dosage changesMonths